SEC Company Response from Korro Bio, Inc. (KRRO) (CIK 0001703647) (KRRO) — Sep 30, 2019
Korro Bio, Inc. (KRRO) (CIK 0001703647)
Date: Sept. 30, 2019 · CIK: 0001703647 · Accession: 0001193125-19-258828
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233652
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Goldman Sachs & Co. LLC
200 West Street
New York, New York
Cowen and Company, LLC
599 Lexington Avenue
New York, New York 10022
September 30, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Donald Field
Re: Frequency Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-233652)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Frequency Therapeutics, Inc. (the “Company”) that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on October 2, 2019, or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff.
Pursuant to Rule 460 under the Act, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated September 23, 2019:
(i) Dates of distribution: September 23, 2019 through the date hereof.
(ii) Number of prospectuses distributed: a total of approximately 3,449 copies of the prospectus were distributed to prospective underwriters, institutional investors, dealers and others.
We have complied and will comply, and have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 September 30, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Re: Frequency Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-233652) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Frequency Therapeutics, Inc. (the “Company”) that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on October 2, 2019, or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff. Pursuant to Rule 460 under the Act, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated September 23, 2019: (i) Dates of distribution: September 23, 2019 through the date hereof. (ii) Number of prospectuses distributed: a total of approximately 3,449 copies of the prospectus were distributed to prospective underwriters, institutional investors, dealers and others. We have complied and will comply, and have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, J.P. MORGAN SECURITIES LLC GOLDMAN, SACHS & CO. LLC COWEN AND COMPANY, LLC As Representatives of the Underwriters By: J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Executive Director By: GOLDMAN SACHS & CO. LLC By: /s/ Lyla Bibi Name: Lyla Bibi Title: Managing Director By: COWEN AND COMPANY, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director